Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company, 73710 [2020-25569]
Download as PDF
<![CDATA[
73710
Federal Register / Vol. 85, No. 224 / Thursday, November 19, 2020 / Notices
to provide information to enable the
Board to carry out the provisions of the
subsection (15 U.S.C. 1693o–2(a)(3)(B)).
The obligation of issuers to respond to
the issuer survey is mandatory. The
Board generally regards the information
collected from each individual issuer on
the FR 3063a survey as confidential
commercial and financial information,
which is protected by exemption 4 of
the Freedom of Information Act (5
U.S.C. 552(b)(4)). The Board, however,
may publicly release aggregate or
summary information in a way that does
not reveal the individual issuer.
Board of Governors of the Federal Reserve
System, November 16, 2020.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2020–25582 Filed 11–18–20; 8:45 am]
BILLING CODE 6210–01–P
Board of Governors of the Federal Reserve
System, November 16, 2020.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
FEDERAL RESERVE SYSTEM
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
[FR Doc. 2020–25569 Filed 11–18–20; 8:45 am]
BILLING CODE 6210–01–P
The notificants listed below have
applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
applications are set forth in paragraph 7
of the Act (12 U.S.C. 1817(j)(7)).
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in paragraph 7 of
the Act.
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than December 4, 2020.
A. Federal Reserve Bank of Atlanta
(Kathryn Haney, Assistant Vice
President) 1000 Peachtree Street NE,
Atlanta, Georgia 30309. Comments can
also be sent electronically to
Applications.Comments@atl.frb.org:
VerDate Sep<11>2014
19:40 Nov 18, 2020
Jkt 253001
1. Jeremy Francis Gilpin, South Lake
Tahoe, California, and Jeffrey Alan
Smith, Atlanta, Georgia, as a group
acting in concert; to acquire voting
shares of Community Bankshares, Inc.,
and thereby indirectly acquire voting
shares of Community Bank and Trust—
West Georgia, both of LaGrange,
Georgia.
B. Federal Reserve Bank of Dallas
(Robert L. Triplett III, Senior Vice
President) 2200 North Pearl Street,
Dallas, Texas 75201–2272:
1. Elizabeth L. Morgan, Austin, Texas,
as trust protector of fifteen trusts
associated with Mr. James W. Collins,
McAllen, Texas; to acquire control of
voting shares of VBT Financial
Corporation, and thereby indirectly
acquire control of voting shares of
Vantage Bank Texas, both of San
Antonio, Texas.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Supplemental Evidence and Data
Request on Integrated Pain
Management Programs
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Request for Supplemental
Evidence and Data Submissions.
AGENCY:
The Agency for Healthcare
Research and Quality (AHRQ) is seeking
scientific information submissions from
the public. Scientific information is
being solicited to inform our review on
Integrated Pain Management Programs,
which is currently being conducted by
the AHRQ’s Evidence-based Practice
Centers (EPC) Program. Access to
published and unpublished pertinent
scientific information will improve the
quality of this review.
DATES: Submission Deadline on or
before December 21, 2020.
ADDRESSES:
Email submissions: epc@
ahrq.hhs.gov.
Print submissions:
Mailing Address: Center for Evidence
and Practice Improvement, Agency for
Healthcare Research and Quality,
ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A,
Rockville, MD 20857.
SUMMARY:
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Shipping Address (FedEx, UPS, etc.):
Center for Evidence and Practice
Improvement, Agency for Healthcare
Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers Lane,
Mail Stop 06E77D, Rockville, MD
20857.
FOR FURTHER INFORMATION CONTACT:
Jenae Benns, Telephone: 301–427–1496
or Email: epc@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION: The
Agency for Healthcare Research and
Quality has commissioned the
Evidence-based Practice Centers (EPC)
Program to complete a review of the
evidence for Integrated Pain
Management Programs. AHRQ is
conducting this systematic review
pursuant to Section 902 of the Public
Health Service Act, 42 U.S.C. 299a.
The EPC Program is dedicated to
identifying as many studies as possible
that are relevant to the questions for
each of its reviews. In order to do so, we
are supplementing the usual manual
and electronic database searches of the
literature by requesting information
from the public (e.g., details of studies
conducted). We are looking for studies
that report on Integrated Pain
Management Programs, including those
that describe adverse events. The entire
research protocol is available online at:
https://effectivehealthcare.ahrq.gov/
products/integrated-pain-management/
protocol.
This is to notify the public that the
EPC Program would find the following
information on Integrated Pain
Management Programs helpful:
D A list of completed studies that
your organization has sponsored for this
indication. In the list, please indicate
whether results are available on
ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
D For completed studies that do not
have results on ClinicalTrials.gov, a
summary, including the following
elements: Study number, study period,
design, methodology, indication and
diagnosis, proper use instructions,
inclusion and exclusion criteria,
primary and secondary outcomes,
baseline characteristics, number of
patients screened/eligible/enrolled/lost
to follow-up/withdrawn/analyzed,
effectiveness/efficacy, and safety results.
D A list of ongoing studies that your
organization has sponsored for this
indication. In the list, please provide the
ClinicalTrials.gov trial number or, if the
trial is not registered, the protocol for
the study including a study number, the
study period, design, methodology,
indication and diagnosis, proper use
instructions, inclusion and exclusion
E:\FR\FM\19NON1.SGM
19NON1
]]>Agencies
[Federal Register Volume 85, Number 224 (Thursday, November 19, 2020)]
[Notices]
[Page 73710]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-25569]
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Change in Bank Control Notices; Acquisitions of Shares of a Bank
or Bank Holding Company
The notificants listed below have applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and Sec. 225.41 of the Board's
Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank
holding company. The factors that are considered in acting on the
applications are set forth in paragraph 7 of the Act (12 U.S.C.
1817(j)(7)).
The public portions of the applications listed below, as well as
other related filings required by the Board, if any, are available for
immediate inspection at the Federal Reserve Bank(s) indicated below and
at the offices of the Board of Governors. This information may also be
obtained on an expedited basis, upon request, by contacting the
appropriate Federal Reserve Bank and from the Board's Freedom of
Information Office at https://www.federalreserve.gov/foia/request.htm.
Interested persons may express their views in writing on the standards
enumerated in paragraph 7 of the Act.
Comments regarding each of these applications must be received at
the Reserve Bank indicated or the offices of the Board of Governors,
Ann E. Misback, Secretary of the Board, 20th Street and Constitution
Avenue NW, Washington, DC 20551-0001, not later than December 4, 2020.
A. Federal Reserve Bank of Atlanta (Kathryn Haney, Assistant Vice
President) 1000 Peachtree Street NE, Atlanta, Georgia 30309. Comments
can also be sent electronically to [email protected]:
1. Jeremy Francis Gilpin, South Lake Tahoe, California, and Jeffrey
Alan Smith, Atlanta, Georgia, as a group acting in concert; to acquire
voting shares of Community Bankshares, Inc., and thereby indirectly
acquire voting shares of Community Bank and Trust--West Georgia, both
of LaGrange, Georgia.
B. Federal Reserve Bank of Dallas (Robert L. Triplett III, Senior
Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:
1. Elizabeth L. Morgan, Austin, Texas, as trust protector of
fifteen trusts associated with Mr. James W. Collins, McAllen, Texas; to
acquire control of voting shares of VBT Financial Corporation, and
thereby indirectly acquire control of voting shares of Vantage Bank
Texas, both of San Antonio, Texas.
Board of Governors of the Federal Reserve System, November 16,
2020.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2020-25569 Filed 11-18-20; 8:45 am]
BILLING CODE 6210-01-P
